Company intelligence / Profile preview

Tavros Therapeutics

Durham, North Carolina, USAvividion.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Tavros developed a proprietary functional genomics platform that identifies new druggable cancer targets through synthetic lethality mapping. The company validated its approach through strategic partnerships and was acquired by Vividion Therapeutics after demonstrating the ability to uncover previously undruggable oncology targets. No clinical results have been published as the pipeline appears preclinical/discovery stage at time of acquisition.

Therapeutic areas: OtherOncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Zentalis PharmaceuticalsOpenBench, Inc.Vividion Therapeutics/Bayer AG

Beyond the preview

Go deeper on Tavros Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tavros Therapeutics.

Explore the full profile